Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Scott Janiczak
Observed name:
S. Janiczak
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
ORCID:
0009-0005-8794-9749
Observed ORCID:
0009-0005-8794-9749
OpenAlex ID:
A5075000812
An Evaluation of Duplicate Adverse Event Reports Characteristics in the Food and Drug Administration Adverse Event Reporting System
2025
·
Scott Janiczak
, Sarah Tanveer
, et al.
·
Drug Safety
·
17
PDF
Social media for early characterization of pandemic symptoms: A qualitative analysis of patient‐reported COVID ‐19 experiences
2022
·
Melissa Khashei
, Scott Janiczak
, et al.
·
Pharmacoepidemiology and Drug Safety
·
7
Correction: An Evaluation of Duplicate Adverse Event Reports Characteristics in the Food and Drug Administration Adverse Event Reporting System
2025
·
Scott Janiczak
, Sarah Tanveer
, et al.
·
Drug Safety
·
1
PDF
Severe Cutaneous Adverse Reactions in Pirfenidone-treated Patients: A Case Series
2023
·
S. Janiczak
, L. Wolf
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
1
Show more works
View as search
Works count:
4
Citation count:
26
H-index:
2
I10-index:
1
Year
Topic
Type